Market closed

Prothena/$PRTA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Prothena

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Ticker

$PRTA
Trading on

Industry

Biotechnology

Headquarters

Dublin, Ireland

Employees

173

Prothena Metrics

BasicAdvanced
$934M
Market cap
-
P/E ratio
-$0.95
EPS
0.20
Beta
-
Dividend rate
$934M
0.2
$41.55
$15.30
487K
12.536
12.068
1.639
2.082
-8.36%
-8.75%
4.29
1.6
1.6
-9.24
276.98%
-66.06%
52.92%
-17.87%

What the Analysts think about Prothena

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Prothena stock.

Prothena Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Prothena Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRTA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Prothena stock?

Prothena (PRTA) has a market cap of $934M as of November 13, 2024.

What is the P/E ratio for Prothena stock?

The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of November 13, 2024.

Does Prothena stock pay dividends?

No, Prothena (PRTA) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Prothena dividend payment date?

Prothena (PRTA) stock does not pay dividends to its shareholders.

What is the beta indicator for Prothena?

Prothena (PRTA) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.